尿钼与乳腺癌风险的关联研究

Association between Urinary Molybdenum and Risk of Breast Cancer

目的探讨尿钼水平与乳腺癌发生风险的关联。方法 2009年10月至2010年7月,对中山大学两家附属医院新诊断的240名女性乳腺癌患者及246名年龄匹配的健康女性对照进行问卷调查和尿样收集。应用秩和检验和多变量统计等方法分析尿钼与乳腺癌的关联。结果尿钼值(中位数μg/g)在健康女性中为72.68μg/g,在乳腺癌女性中为85.20μg/g,两者比较差异有统计学意义(P=0.03)。与最低尿钼分位比,中尿钼水平有降低乳腺癌风险趋势,高尿钼水平则有增加乳腺癌风险趋势,但其差异均未达统计学意义。在绝经女性中,最高三份位与最低三份位尿钼水平比较,乳腺癌风险显著增加(OR=2.35,95%CI=1.13~4.92)。结论适量水平的钼可能具有抑制乳腺癌作用;而高水平钼则可能具有潜在致乳腺癌作用(特别对于绝经女性)。

Objective To explore the association between urinary molybdenum and the risk of breast cancer. Methods Questionnaire survey and urine sample collection were applied on 240 female breast cancer patients and 246 healthy and age-matched controls in two Affiliated Hospitals of Sun Yat-sen University from Oct. 2009 to July 2010. Rank test and multivariate analysis were used to estimate the association between urinary molybdenum and risk of breast cancer. Results Creatinine-adjusted urine levels of molybdenum(median μg/g) were 85.20 μg/g in female breast cancer patients and 72.68 μg/g in the controls, with statistically significant difference. There was a tendency that the intermediate tertile was associated with a lower risk of breast cancer while the highest tertile increased the risk of breast cancer, compared with the lowest tertile, with no statistical significance. Postmenopausal women in the highest tertile of urine molybdenum showed a significant increased risk of breast cancer, compared with those in the lowest tertile(OR=2.35, 95%CI=1.13-4.92). Conclusion A moderate level of Molybdenum may have inhibitory effect of breast cancer; while a high level of Molybdenum may increase the risk of breast cancer, especially for postmenopausal women.